- Email: [email protected]
JCOG activities in geriatric oncology
Abstracts
POS-03 JCOG ACTIVITIES IN GERIATRIC ONCOLOGY F. Nagashima1,⁎ Department of Medical Oncology, Kyorin University School of Medicine, Mitaka-shi, Tokyo, Japan
Introduction: In Japan, there are few national strategies towards the treatment of elderly cancer patients specifically, and geriatric oncology is not an area that has attracted much attention previously. Japan Clinical Oncology Group (JCOG) is the largest cooperative group in Japan, funded by the ministry of health, labor and welfare of Japanese government. We just established the Geriatric Study Committee in December 2013. Objectives: The goal of this committee is to make a policy to promote clinical trials for older patients with 3 major tasks: (1) Create a clear and operational definition of vulnerability/frailty applicable to oncology, (2) Develop, test and disseminate geriatric assessments, (3) Improve research in the field of geriatric oncology, in collaboration with SIOG as needed. JCOG1018 is a randomized phase III study of mFOLFOX7 or CAPOX plus bevacizumab versus 5fluorouracil/leucovorin or capecitabine plus bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Primary purpose is to compare the progression-free survival (PFS) of elderly patients who are randomized to receive fluoropyrimidinebased therapy (5-FU/LV or capecitabine) plus bevacizumab, with or without oxaliplatin. This study includes geriatric assessments (VES13) before chemotherapy. Methods: The Cancer-Specific Geriatric Assessment (CSGA) is a brief, widely adopted, multidimensional assessment for older patients with cancer. We developed and tested the feasibility of a computer-based CSGA in Japanese patients ≥65 years of age with advanced cancer. Results: The translation and back-translation processes were repeated until the back-translated CSGA was identical to the original CSGA, with Dr. Hurria's kind cooperation. Conclusion: We are now preparing an additional evaluation of CSGA in JCOG1018 trial. I will share recent JCOG activities in Geriatric Oncology. Disclosure of interest: None declared. Keywords: Colorectal. doi:10.1016/j.jgo.2014.06.020
POS-04 TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS DIAGNOSED AT DIFFERENT AGE PRESENT SIMILAR CLINICOPATHOLOGICAL FEATURES, BUT DIFFERENT TREATMENT AND PROGNOSIS IN CHINESE POPULATION F. Fei1,⁎, L. Tang1, G. Di1, J. Wu1, Z. Shao1 1 Breast Surgery Department, Shanghai Cancer Center Fudan University, Shanghai, China
Introduction: Triple negative breast cancer (TNBC) patients have its own features across the ages. Objectives: To describe the clinicopathological features, treatment and prognosis of TNBC in Chinese women diagnosed at different age, we conduct our retrospective study on 217 elderly (≥65 years), 605 middle-age (41–64 years) and 243 young (≤40 years) patients who underwent surgery in our hospital. Methods: We compare the clinical characteristics, treatment and the occurrences of relapse in three age cohorts by means of Spearman's rank correlation analysis and Kruskal–Wallis test. The
S9
Kaplan–Meier method and log rank test are used for calculating relapse-free survival (RFS), distant relapse free survival (DRFS) and disease specific survival (DSS). Results: Median follow-up is 5.8 years. TNBC patients present similar clinicopathological features at whichever age they are diagnosed. Chinese elderly TNBC patients have equivalent disease specific survival (young 79.5% vs elderly 80.1% vs middle-age 82.4%, p N 0.05) in spite of substantially less treatments (radiotherapy:elderly 23.50% vs middle-age 44.46% vs young 62.55%, p = 0.033 and chemotherapy: elderly 48.39% vs middle-age 94.71% vs young 92.18%, p b 0.001). 5 year RFS (young 75.9% vs elderly 81.2% vs middle-age 83.3%, p b 0,05) and DRFS (young 82.3% vs elderly 87.0% vs middle-age 88.6%, p b 0,05) are observed significantly worse in the patients at age ≤40 years. Conclusion: Our results indicate that there are various heterogeneity entities across the age groups for TNBC tumors in Chinese population. Disclosure of interest: None declared. Keywords: Breast cancer. References [1] Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol 2009;36:237–249. [2] Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One 2009;4:e7695. [3] Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13(pt 1):4429–4434. [4] Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275–1281. [5] Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst Nov 19 2008;100(22):1643–1648. [6] Ihemelandu CU, Leffall Jr LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, et al. Molecular breast cancer subtypes in premenopausal African–American women, tumor biologic factors and clinical outcome. Ann Surg Oncol Oct 2007;14(10):2994–3003. [7] Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN, et al. The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat Apr 2013;138(2):591–599. [8] Aapro M, Wildiers H. Triple-negative breast cancer in the older population. Ann Oncol Aug 2012;23(Suppl 6):vi52–vi55. [9] Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat Feb 2012;131(3):1061–1066. doi:10.1016/j.jgo.2014.06.021
POS-05 HISTOLOGY AND BIOLOGIC PROFILE OF BREAST CANCER IN ELDERLY OF BALINESE POPULATION P.K.A. Prayudi1,⁎, A.Y. Permatasari1, P.A.T. Adiputra2 1 Faculty of Medicine Udayana University, Surgery Department, Sanglah General Hospital, Denpasar, Indonesia 2 Division of Surgical Oncology, Surgery Department, Sanglah General Hospital, Denpasar, Indonesia
Introduction: Histologic subtype and expression profile of specific protein markers are important prognostic determinants of
POS-03 JCOG ACTIVITIES IN GERIATRIC ONCOLOGY F. Nagashima1,⁎ Department of Medical Oncology, Kyorin University School of Medicine, Mitaka-shi, Tokyo, Japan
Introduction: In Japan, there are few national strategies towards the treatment of elderly cancer patients specifically, and geriatric oncology is not an area that has attracted much attention previously. Japan Clinical Oncology Group (JCOG) is the largest cooperative group in Japan, funded by the ministry of health, labor and welfare of Japanese government. We just established the Geriatric Study Committee in December 2013. Objectives: The goal of this committee is to make a policy to promote clinical trials for older patients with 3 major tasks: (1) Create a clear and operational definition of vulnerability/frailty applicable to oncology, (2) Develop, test and disseminate geriatric assessments, (3) Improve research in the field of geriatric oncology, in collaboration with SIOG as needed. JCOG1018 is a randomized phase III study of mFOLFOX7 or CAPOX plus bevacizumab versus 5fluorouracil/leucovorin or capecitabine plus bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Primary purpose is to compare the progression-free survival (PFS) of elderly patients who are randomized to receive fluoropyrimidinebased therapy (5-FU/LV or capecitabine) plus bevacizumab, with or without oxaliplatin. This study includes geriatric assessments (VES13) before chemotherapy. Methods: The Cancer-Specific Geriatric Assessment (CSGA) is a brief, widely adopted, multidimensional assessment for older patients with cancer. We developed and tested the feasibility of a computer-based CSGA in Japanese patients ≥65 years of age with advanced cancer. Results: The translation and back-translation processes were repeated until the back-translated CSGA was identical to the original CSGA, with Dr. Hurria's kind cooperation. Conclusion: We are now preparing an additional evaluation of CSGA in JCOG1018 trial. I will share recent JCOG activities in Geriatric Oncology. Disclosure of interest: None declared. Keywords: Colorectal. doi:10.1016/j.jgo.2014.06.020
POS-04 TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS DIAGNOSED AT DIFFERENT AGE PRESENT SIMILAR CLINICOPATHOLOGICAL FEATURES, BUT DIFFERENT TREATMENT AND PROGNOSIS IN CHINESE POPULATION F. Fei1,⁎, L. Tang1, G. Di1, J. Wu1, Z. Shao1 1 Breast Surgery Department, Shanghai Cancer Center Fudan University, Shanghai, China
Introduction: Triple negative breast cancer (TNBC) patients have its own features across the ages. Objectives: To describe the clinicopathological features, treatment and prognosis of TNBC in Chinese women diagnosed at different age, we conduct our retrospective study on 217 elderly (≥65 years), 605 middle-age (41–64 years) and 243 young (≤40 years) patients who underwent surgery in our hospital. Methods: We compare the clinical characteristics, treatment and the occurrences of relapse in three age cohorts by means of Spearman's rank correlation analysis and Kruskal–Wallis test. The
S9
Kaplan–Meier method and log rank test are used for calculating relapse-free survival (RFS), distant relapse free survival (DRFS) and disease specific survival (DSS). Results: Median follow-up is 5.8 years. TNBC patients present similar clinicopathological features at whichever age they are diagnosed. Chinese elderly TNBC patients have equivalent disease specific survival (young 79.5% vs elderly 80.1% vs middle-age 82.4%, p N 0.05) in spite of substantially less treatments (radiotherapy:elderly 23.50% vs middle-age 44.46% vs young 62.55%, p = 0.033 and chemotherapy: elderly 48.39% vs middle-age 94.71% vs young 92.18%, p b 0.001). 5 year RFS (young 75.9% vs elderly 81.2% vs middle-age 83.3%, p b 0,05) and DRFS (young 82.3% vs elderly 87.0% vs middle-age 88.6%, p b 0,05) are observed significantly worse in the patients at age ≤40 years. Conclusion: Our results indicate that there are various heterogeneity entities across the age groups for TNBC tumors in Chinese population. Disclosure of interest: None declared. Keywords: Breast cancer. References [1] Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol 2009;36:237–249. [2] Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One 2009;4:e7695. [3] Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13(pt 1):4429–4434. [4] Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275–1281. [5] Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst Nov 19 2008;100(22):1643–1648. [6] Ihemelandu CU, Leffall Jr LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, et al. Molecular breast cancer subtypes in premenopausal African–American women, tumor biologic factors and clinical outcome. Ann Surg Oncol Oct 2007;14(10):2994–3003. [7] Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN, et al. The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat Apr 2013;138(2):591–599. [8] Aapro M, Wildiers H. Triple-negative breast cancer in the older population. Ann Oncol Aug 2012;23(Suppl 6):vi52–vi55. [9] Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat Feb 2012;131(3):1061–1066. doi:10.1016/j.jgo.2014.06.021
POS-05 HISTOLOGY AND BIOLOGIC PROFILE OF BREAST CANCER IN ELDERLY OF BALINESE POPULATION P.K.A. Prayudi1,⁎, A.Y. Permatasari1, P.A.T. Adiputra2 1 Faculty of Medicine Udayana University, Surgery Department, Sanglah General Hospital, Denpasar, Indonesia 2 Division of Surgical Oncology, Surgery Department, Sanglah General Hospital, Denpasar, Indonesia
Introduction: Histologic subtype and expression profile of specific protein markers are important prognostic determinants of